NCT00855517撤回2 期
A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- IOP change from baseline
研究概览
简要总结
The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Over 18 yrs of age with ocular hypertension or open-angle glaucoma
- •Subjects who have a best corrected visual acuity of 20/100 or better
排除标准
- •Subjects who wear contact lenses.
- •Uncontrolled medical conditions
- •Subjects requiring chronic topical artifical tears, lubricants and/or requiring any other chronic topical medications
- •Subjects who have a history of chronic or recurrent inflammatory eye disease
研究组 & 干预措施
Punctal Plug
Experimental
干预措施: Latanoprost-PPDS (Drug)
结局指标
主要结局
IOP change from baseline
时间窗: 6 weeks
次要结局
未报告次要终点
研究者
相似试验
Unknown
2 期
Latanoprost for the Treatment of Menière's DiseaseMenière's DiseaseNCT01973114Synphora AB100
已完成
2 期
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle GlaucomaGlaucomaOcular Hypertension (OH)NCT01481051Mati Therapeutics Inc.57
已完成
2 期
A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle GlaucomaOpen-Angle GlaucomaOcular HypertensionNCT02014142Mati Therapeutics Inc.86
已完成
2 期
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle GlaucomaGlaucomaOcular HypertensionNCT00820300Mati Therapeutics Inc.113
已完成
2 期
A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAGOpen-Angle GlaucomaOcular HypertensionNCT01037036Mati Therapeutics Inc.15